Clinical Course after Intravitreal Bevacizumab Injection in Ischemic Central Retinal Vein Obstruction.

Yoo, Eun Seok; Lew, Young Ju; Choi, Moon Jung; Han, Jung Il; Yoo, Soo Jin; Lee, Dong Won; Cho, Sung Won; Kim, Chul Goo; Lee, Tae Gon; Kim, Jong Woo; Lee, Jae Heung

doi:2011.52.10.1202

J Korean Ophthalmol Soc > Volume 52(10); 2011 > Article

Original Article

Journal of the Korean Ophthalmological Society 2011;52(10):1202-1207.
DOI: https://doi.org/10.3341/jkos.2011.52.10.1202 Published online October 15, 2011.

Clinical Course after Intravitreal Bevacizumab Injection in Ischemic Central Retinal Vein Obstruction.

Eun Seok Yoo, Young Ju Lew, Moon Jung Choi, Jung Il Han, Soo Jin Yoo, Dong Won Lee, Sung Won Cho, Chul Goo Kim, Tae Gon Lee, Jong Woo Kim, Jae Heung Lee

¹Myung-Gok Eye Research Institute, Kim's Eye Hospital, Seoul, Korea. yjlew@kimeye.com
²Department of Ophthalmology, College of Medicine, Konyang University, Daejeon, Korea.

허혈성 망막중심정맥폐쇄에서 유리체내 베바시주맙 주입 후 임상경과

유은석¹⋅유영주¹⋅최문정¹⋅한정일¹⋅유수진¹⋅이동원¹⋅조성원¹⋅김철구¹⋅이태곤²⋅김종우¹⋅이재흥¹

Myung-Gok Eye Research Institute, Kim’s Eye Hospital¹, Seoul, Korea Department of Ophthalmology, College of Medicine, Konyang University², Daejeon, Korea

Abstract

PURPOSE
To determine the clinical outcome of intravitreal bevacizumab injection in patients with ischemic central retinal vein obstruction (CRVO). METHODS: The present study was conducted retrospectively on 56 eyes of 56 patients who were diagnosed with CRVO and classified according to ischemic and non-ischemic type and underwent an intravitreal bevacizumab injection. The present study measured changes in visual acuity and central macular thickness, neovascularization in the anterior segment, development of neovascular glaucoma and other clinical complications. RESULTS: The average number of bevacizumab injections in both groups was 2.07 and 1.62 in the ischemic type. No patients developed neovascular glaucoma in the non-ischemic type group, 14 of 26 eyes in the ischemic type group developed neovascular glaucoma and the mean time to diagnosis was 28.75 weeks. log MAR visual acuity of the ischemic type group prior to injection was 1.56 +/- 0.65 on average which improved to 1.44 +/- 0.97 (p = 0.45). CONCLUSIONS: Intravitreal bevacizumab injection improves the condition of cystic macular edema clinically, but does not affect the development of neovascular glaucoma and improvement of visual acuity in ischemic type CRVO.

Key Words: Central retinal vein obstruction;Intravitreal bevacizumab injection;Neovacular glaucoma